893441-59-3 Usage
Uses
Used in Pharmaceutical Industry:
(E)-1-(1-BENZOTHIOPHEN-2-YL)-3-(DIMETHYLAMINO)-2-PROPEN-1-ONE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique molecular structure and potential biological activities contribute to the development of new drugs with specific therapeutic targets.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (E)-1-(1-BENZOTHIOPHEN-2-YL)-3-(DIMETHYLAMINO)-2-PROPEN-1-ONE serves as a valuable compound for studying its interactions with biological targets, such as enzymes, receptors, and other proteins. This research can lead to a better understanding of its potential applications in drug discovery and development.
Used in Drug Development:
(E)-1-(1-BENZOTHIOPHEN-2-YL)-3-(DIMETHYLAMINO)-2-PROPEN-1-ONE is utilized in the development of novel therapeutic agents, particularly for conditions that require targeted treatment. Its structural properties and potential biological activities make it a suitable candidate for the design and synthesis of new drugs with improved efficacy and selectivity.
Further research is necessary to fully comprehend the potential uses and effects of (E)-1-(1-benzothiophen-2-yl)-3-(dimethylamino)-2-propen-1-one, as its applications in different industries may vary based on the specific requirements and objectives of each field.
Check Digit Verification of cas no
The CAS Registry Mumber 893441-59-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,3,4,4 and 1 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 893441-59:
(8*8)+(7*9)+(6*3)+(5*4)+(4*4)+(3*1)+(2*5)+(1*9)=203
203 % 10 = 3
So 893441-59-3 is a valid CAS Registry Number.
893441-59-3Relevant academic research and scientific papers
AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
-
Page/Page column 38, (2010/11/08)
The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.
